MyFinsight
Home
Blog
About
Accounts receivable, net
$200,000K
(60.69%↑ Y/Y)
Marketable securities
$167,000K
(-46.35%↓ Y/Y)
Cash and cash
equivalents
$125,000K
(-29.10%↓ Y/Y)
Inventory
$59,000K
(26.89%↑ Y/Y)
Prepaid expenses and
other assets
$55,000K
(-10.19%↓ Y/Y)
Total current assets
$606,000K
(-15.81%↓ Y/Y)
Property, plant, and
equipment, net
$235,000K
(-8.12%↓ Y/Y)
Intangible assets, net
$172,000K
(-1.56%↓ Y/Y)
Marketable securities
$144,000K
(179.86%↑ Y/Y)
Other assets
$63,000K
(4.79%↑ Y/Y)
Goodwill
$44,000K
(-0.91%↓ Y/Y)
Total assets
$1,264,000K
(-3.24%↓ Y/Y)
Accumulated deficit
-$4,809,000K
(-13.88%↓ Y/Y)
Treasury stock, at cost,
0.3 shares in 2026...
$10,000K
(25.14%↑ Y/Y)
Total liabilities,
noncontrolling interest and...
$1,264,000K
(-3.24%↓ Y/Y)
Total stockholders'
deficit
-$291,000K
(-292.35%↓ Y/Y)
Additional paid-in capital
$4,518,000K
(3.28%↑ Y/Y)
Deferred compensation
obligation
$10,000K
(25.14%↑ Y/Y)
Total liabilities
$1,548,000K
(34.85%↑ Y/Y)
Noncontrolling interest
$7,000K
(0.00%↑ Y/Y)
Liabilities for sales of
future royalties
$1,126,000K
(43.85%↑ Y/Y)
Total current
liabilities
$351,000K
(19.70%↑ Y/Y)
Other liabilities
$41,000K
(135.66%↑ Y/Y)
Deferred tax liabilities
$30,000K
(-0.19%↓ Y/Y)
Accrued liabilities
$221,000K
(22.24%↑ Y/Y)
Liabilities for sales of
future royalties
$76,000K
(19.00%↑ Y/Y)
Accounts payable
$39,000K
(13.90%↑ Y/Y)
Other liabilities
$15,000K
(481.17%↑ Y/Y)
Back
Back
Balance Sheet
Ultragenyx Pharmaceutical Inc. (RARE)
Ultragenyx Pharmaceutical Inc. (RARE)
source: myfinsight.com